A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes ...
Investor's Business Daily on MSN56m
Novo Nordisk Surges As Next-Gen Obesity Drug OutperformsNovo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback